Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio and Shephard Mpofu
The Journal of Rheumatology January 2014, jrheum.130637; DOI: https://doi.org/10.3899/jrheum.130637
Mark C. Genovese
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Durez
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanno B. Richards
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerzy Supronik
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Dokoupilova
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob A. Aelion
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sang-Heon Lee
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Codding
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herbert Kellner
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Ikawa
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Hugot
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Ligozio
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shephard Mpofu
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. Supported by an unrestricted grant from Novartis Pharma AG, Basel, Switzerland. M.C. Genovese, MD, Stanford University; P. Durez, MD, Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc; H.B. Richards, MD, PhD, Novartis Pharma AG; J. Supronik, MD, PhD, NZOZ Centrum Medyczne Artur Racewicz; E. Dokoupilova, MD, Medical Plus; J.A. Aelion, MD, Arthritis Clinic; S-H. Lee, MD, Konkuk University Medical Center; C.E. Codding, MD, Health Research of Oklahoma; H. Kellner, MD, Centre for Inflammatory Joint Diseases; T. Ikawa, MD, Kobe-Konan Yamate Clinic; S. Hugot, MSc, Novartis Pharma AG; G. Ligozio, MS, Novartis Pharmaceuticals Corporation; S. Mpofu, MD, FRCP, Novartis Pharma AG. Address correspondence to Dr. M.C. Genovese, Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road #203, Palo Alto, California 94304, USA. E-mail: genovese@stanford.edu Accepted for publication November 8, 2013.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
Next
Loading

Abstract

Objective To evaluate the longer-term safety and efficacy of secukinumab, a fully human monoclonal antiinterleukin-17A antibody, in patients with rheumatoid arthritis.

Methods In this 52-week, double-blind, placebo-controlled (up to Week 20) study (NCT00928512), patients responding inadequately to disease-modifying antirheumatic drugs (DMARD) or biologics were randomized to receive monthly subcutaneous injections of secukinumab (25, 75, 150, or 300 mg), or placebo. The efficacy and safety results up to Week 20 have been reported previously. Here, efficacy results from Week 20 to 52 and safety results from Week 20 to 60 are presented.

Results Of 237 patients randomized, 174 (73.4%) completed the study. Patients with improved American College of Rheumatology (ACR) and 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) responses at Week 16 sustained their responses through Week 52. In patients taking 150 mg of secukinumab, responses were improved through Week 52 (ACR50: Week 16 = 45%, Week 52 = 55%; DAS28-CRP ≤ 2.6: Week 16 = 25%, Week 52 = 40%). The rate of adverse events (AE) from weeks 20 to 60 was 64.8%, with most AE being mild to moderate in severity. The overall rate of infections was 31.9%, most being mild. The most predominant infection was nasopharyngitis, and was not associated with dose or concurrent neutropenia. Serious AE were reported in 21 patients (8.9%). There were 3 reports of malignancies (ovarian, lung, basal cell), and no deaths between weeks 20 and 60.

Conclusion Patients with active RA who failed to respond to DMARD and other biologics showed an improvement after longterm treatment with 150 mg of secukinumab. The frequency of AE remained stable over time and secukinumab had a consistent safety profile over 60 weeks.

Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilova, Jacob A. Aelion, Sang-Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu
The Journal of Rheumatology Jan 2014, jrheum.130637; DOI: 10.3899/jrheum.130637
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Understanding the Psoriasis Phenotype Associated With Psoriatic Arthritis Using the PURE-4 Questionnaire: Insights From Spanish Real-World Settings
  • HLA-B27 Testing in Clinical Practice: A Retrospective Analysis of Testing Indications and Rheumatology Referral Patterns
  • Analysis of Gut-Homing Receptors in Circulating Mucosal-Associated Invariant T Cells and Their Presence in Synovial Tissue From Patients With Axial Spondyloarthritis
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire